News About: Pharm. Affairs
Is the biopharmaceutical field just like chasing a mirage?
It was recently analyzed the biopharmaceutical industry has not enough capability to be responsible for the future of a nation, although interests in the industry is explosive. Particularly, it is expected that its gr...
Rare disease drugs will be consigned for manufacturing by domestic pharmaceutical companies
Domestic pharmaceutical companies will be able to consign manufacturing of rare disease drugs and pharmaceutical products that are promptly required to be introduced in Korea.
On the 24th, the Ministry of Food and Dr...
Upturn of obesity treatments even in 1st quarter considered as off-season
The obesity treatment market which has been depressed for a while has recently taken an upturn from the introduction of new drugs.
Since ‘Belviq(Ildong Pharmaceutical),’ the new obesity therapy which acquired approva...
Lilly and Samsung fueled competition in biosimilar insulin market
Biosimilar developers will now aim for the insulin market. Their target is ‘Lantus,’ the one prescribed the most.
According to the industry concerned on the 24th, the first biosimilar of Lantus(insulin glargine) was...
Will Multaq fly in antiarrhythmic market with removal of insurance standard condition?
The Sanofi’s antiarrhythmic drug ‘Multaq(generic name: dronedarone)’ seems to be easy on its usage in the clinical field due to relaxation of the health insurance standard.
The Ministry of Health and Welfare(MOHW) ga...
RSA drugs are cruising after getting insurance benefits
RSA(Risk Sharing Agreement) drugs recorded increased in performance. Except for drugs newly registered as RSA drugs, most products are expected to record billions of sales.
Although the RSA system cannot be evaluate...
Emergency contraceptives decided to remain as ETC
The Korean Pharmaceutical Association(President Chan-hui Jo, KPA) expressed a deep regret for the Ministry of Food and Drug Safety’s(MFDS) decision to keep emergency contraceptives as ETC drugs.
Through a news releas...
Biopharmaceutical product exports reach USD 990 million
Last year, the biopharmaceutical exports were recorded at USD 789.15 million, overcoming the imports of USD 738.22 million, switching the trade balance to surplus.
On the 23rd, the Ministry of Food and Drug Safety(M...
Celebrex 200mg and Miltaq voluntarily cut by 23% and 5% respectively
Multinational pharmaceutical companies have voluntarily cut prices of their major products. They are products, such as Celebrex Cap 200mg, Xalatan Eye Drops and Multaq Tab; their decrease range is 23.4% at the maximum...
Will Boehringer-Lilly’s ‘Jardiance’ bring new atmosphere in diabetes treatment market?
Boehringer Ingelheim and Lilly attracted attention as expected to actively enter the SGLT-2 inhibitor market through launching ‘Jardiance(generic name: empagliflozin).’
Boehringer Ingelheim Korea, Lilly Korea and Yuh...
